The high cost of GLP-1 drugs, used primarily for type 2 diabetes and obesity, are driven by from expensive R&D, complex manufacturing processes, and stringent quality control.

Rising demand, supply chain challenges and counterfeit products further complicate accessibility. To alleviate costs, maintain cold chain integrity and improve distribution efficiency, strategic partnerships with specialized logistics providers are essential.

In this premier industry article, featuring Marken’s Senior Vice-President of Innovation and Strategic Operations, Dan Bell, shares valuable insights on how optimized logistics contribute to lower costs for drugs, like GLP-1’s, providing a deeper understanding of the critical role Marken plays in helping drugs become more accessible to patients. Hear Dan’s perspective on the rising popularity of GLP-1’s and how logistic strategies, such as inventory management, risk mitigation, storage and distribution, as well as streamlining regulatory processes, bring another level of problem-solving to the complexities of these groundbreaking medicines in the ever-evolving pharma supply chain.